KRAS and neoplasm: These differences represent the clearest indication of a rugged landscape of oncogene-tumor suppressor interactions; whether a second step (tumor suppressor inactivation) led uphill or downhill depended strongly on which first uphill step was taken (EGFR or KRAS or BRAF).